Bio-Rad Laboratories (BIO_B) Stock Forecast: StockMap's 2-Week Call
BIO_B stock forecast: StockMap's model leans Outperform on Bio-Rad Laboratories for the two weeks after the Nov 19 close, toward BIO_B doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on BIO_B since Aug 21; by chance, a call on the same dates was right 67% of the time.
Bio-Rad Laboratories last closed at $389.98, +0.00% on the session.
Against the IVW growth benchmark the position is +2.33% over the forecast window.
Bio-Rad Laboratories' market cap is $1.97B as of November 19, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 21 (too close to call).
Where BIO_B sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 9 bullish and 6 bearish.
Agreement across those insights is 60%.
33 daily calls for BIO_B so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Bio-Rad Laboratories in the 82nd percentile on valuation and the 70th percentile on return on equity, where 100 is best.
Bio-Rad Laboratories is classified under Health Care / Life Sciences Tools & Services.
StockMap tracks Bio-Rad Laboratories as the 25th largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.
Across that group the current two-week reads are 23 Neutral, 16 Moderate Outperform and 3 Moderate Underperform.
On that composite Bio-Rad Laboratories ranks 15th of 42 in the group, against a group median of +0.13.